AMENDMENTS TO THE CLAIMS

This listing of claims replaces all prior versions and listings of claims in the application.

Listing of Claims:

1. (Currently Amended) A method of identifying a compound that inhibits binding of MUC1 to a tumor progressor, the method comprising:

(a) providing a MUC1 test agent comprising a YEKV site (SEQ ID NO:11);

(b) providing a tumor progressor test agent that binds to the MUC1 test agent;

(c) contacting the MUC1 test agent with the tumor progressor test agent in the presence of a test compound~~, wherein the test compound is a compound that binds to MUC1~~; and

(d) determining whether the test compound inhibits ~~binding~~phosphorylation of the YEKV site of the MUC1 test agent ~~to the tumor progressor test agent~~,

wherein a test compound that inhibits ~~binding~~phosphorylation of the YEKV site of the MUC1 test agent ~~to a tumor progressor test agent~~ is a compound that inhibits binding of MUC1 to a tumor progressor.

2. (Withdrawn) The method of claim 1, wherein the tumor progressor test agent is a c-Src test agent.

3. (Withdrawn) The method of claim 1, wherein the tumor progressor test agent is a $p120^{ctn}$ test agent.

4. (Withdrawn) The method of claim 1, wherein the tumor progressor test agent is an epidermal growth factor receptor (EGF-R) test agent.

5. (Original) The method of claim 1, wherein the tumor progressor test agent is a β-catenin test agent.

6. (Withdrawn) The method of claim 1, wherein the tumor progressor test agent is a protein kinase Cδ (PKCδ) test agent.

7. (Original) The method of claim 1, wherein the contacting is carried out in a cell-free system.

8. (Original) The method of claim 1, wherein the contacting occurs in a cell.

9. (Currently Amended) A method of identifying a compound that inhibits binding of MUC1 to a tumor progressor, the method comprising:

(a) providing a MUC1 test agent comprising a YEKV site (SEQ ID NO:11);

(b) providing a tumor progressor test agent that binds to the MUC1 test agent;

(c) contacting the MUC1 test agent with the tumor progressor test agent in the presence of a test compound, wherein the test compound is a peptide fragment of the tumor progressor; and

(d) determining whether the test compound inhibits ~~binding~~phosphorylation of the YEKV site of the MUC1 test agent ~~to the tumor progressor test agent~~,

wherein a test compound that inhibits ~~binding~~phosphorylation of the YEKV site of the MUC1 test agent ~~to a tumor progressor test agent~~ is a compound that inhibits binding of MUC1 to a tumor progressor.

10. (Withdrawn) The method of claim 9, wherein the tumor progressor test agent is a c-Src test agent.

11. (Withdrawn) The method of claim 9, wherein the tumor progressor test agent is a $p120^{ctn}$ test agent.

12. (Withdrawn) The method of claim 9, wherein the tumor progressor test agent is an epidermal growth factor receptor (EGF-R) test agent.

13. (Previously Presented) The method of claim 9, wherein the tumor progressor test agent is a β-catenin test agent.

14. (Withdrawn) The method of claim 9, wherein the tumor progressor test agent is a protein kinase Cδ (PKCδ) test agent.

15. (Previously Presented) The method of claim 9, wherein the contacting is carried out in a cell-free system.

16. (Previously Presented) The method of claim 1, wherein the contacting occurs in a cell.

17. (New) The method of claim 1, wherein the MUC1 test agent comprises SEQ ID NO:1.

18. (New) The method of claim 9, wherein the MUC1 test agent comprises SEQ ID NO:1.